News 
Market Data 
Discover
Replies to post #3827 on Pfizer Inc (PFE)
Comment: The main problem with this work is that the demographics of the control group are not reported, so we have no idea if they are similar. This them means that we have no idea if the differences in outcomes are because of the treatment, or if they would be expected because of the demographies of the groups.
A subtler point is that the reported age profile of the treatment group is impossible. Group A is aged >60 years, and almost half of the treatment group was in that group. But the IQR was reported as 40-60, so only 25% of the treatment group had an age >60. I hope this was due to excessive rounding, or a similar error that can be corrected.
Moreover to the fact that the demographics are not known for the untreated groups, the major bias in this study that the authors cannot address and deserve the withdraw of this preprint is that the treated group only group young people or old with no symptom. It is not possible according to the experimental procedure and patient selection to the authors to conclude to any effect of HCQ alone or with any conbination.
There are a number of inconsistencies in the paper that I would like to see clarified. First there is the claim of 405 patients treated in early May and now a paper with only 141 patients 2 months later, which really prompt the question what happened to the other patients and why are they not included. Then there are inconsistencies between table 4 and 5. 77% has a fever (109/141), but only 79/141 have a temperature measurement. The IQR is (37-37.8) which suggests that only 30% have a fever. Group A has an age IQR of (64-69), which suggest that there are only 25% (17 patients) 70 or over. Is this correct ?
Countries that use Hydroxychloroquine for early treatment covid-19 all have very low death rate.
These countries include: India, Russia, Turkey and many mid-east countries. Among them, Qatar has 109,036 people test positive, but only 164 total deaths with a fatality rate 0.15% !!! The country's hospitals are empty even though the infection rate is very high for a small country with 2.8 million population.
Brazil started relatively late due to short of Hydroxychloroquine. President Trump sent 2 millions of pills to Brazil on
May 31st upon the request from Brazil's Bolsonaro
